Skip to main content
Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study
- Krug, U;
- Ravandi, F;
- Ritchie, EK;
- Sayar, H;
- Lancet, JE;
- Craig, MD;
- Vey, N;
- Strickland, SA;
- Schiller, GJ;
- Jabbour, E;
- Erba, HP;
- Pigneux, A;
- Horst, H-A;
- Recher, C;
- Klimek, VM;
- Cortes, J;
- Roboz, GJ;
- Craig, AR;
- Fox, JA;
- Ward, R;
- Smith, JA;
- Acton, G;
- Mehta, C;
- Kantarjian, HM;
- Stuart, RK
Published Web Location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822512/No data is associated with this publication.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.